{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:48:55Z","timestamp":1790693335176,"version":"4.1.0"},"reference-count":244,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.gastrohep.2020.07.001","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T17:42:53Z","timestamp":1597426973000},"page":"1-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"S1","title":["Gu\u00eda GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodolog\u00eda GRADE"],"prefix":"10.1016","volume":"43","author":[{"given":"Beatriz","family":"Sicilia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yago","family":"Gonz\u00e1lez-Lama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamile","family":"Zabana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Gomoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24 Suppl","key":"10.1016\/j.gastrohep.2020.07.001_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/00365528909091339","article-title":"Classification of inflammatory bowel disease","volume":"170","author":"Lennard-Jonnes","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2005\/269076","article-title":"Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of gastroenterology","volume":"19 Suppl A","author":"Silverberg","year":"2005","journal-title":"Can J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/gut.21.3.232","article-title":"Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis","volume":"21","author":"Azad Khan","year":"1980","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0020","first-page":"135","article-title":"Epidemiolog\u00eda de la enfermedad inflamatoria intestinal: controversias en la epidemiolog\u00eda cl\u00e1sica","volume":"39","author":"Sicilia","year":"2009","journal-title":"Acta Gastroenterol Latinoam."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0025","first-page":"1953","article-title":"IBD prevalence in Lothian","volume":"68","author":"Jones","year":"2019","journal-title":"Scotland, derived by capture-recapture methodology. Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0030","first-page":"17","article-title":"The\u00a0global regional, and\u00a0national\u00a0burden\u00a0of\u00a0inflammatory\u00a0bowel\u00a0disease\u00a0in\u00a0195\u00a0countries\u00a0and territories, 1990-2017: a systematic analysis for the\u00a0Global\u00a0Burden\u00a0of\u00a0Disease\u00a0Study 2017","volume":"5","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0035","first-page":"CD000543","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"4","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0040","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0045","first-page":"1041","article-title":"Cortisone in ulcerative colitis","volume":"2","author":"Truelove","year":"1955","journal-title":"Final report on a therapeutic trial. BMJ."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0050","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ng.764","article-title":"Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47","volume":"43","author":"Anderson","year":"2011","journal-title":"Nat Genet."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0055","unstructured":"Gomoll\u00f3n F, Hinojosa J, Gassull MA editores. Enfermedad Inflamatoria Intestinal. IV edici\u00f3n. ERGON Mahadahonda Madrid. ISBN 978-84-17194-63-5."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0060","series-title":"Inflammatory bowel disease.","year":"2010"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0065","series-title":"Improving patient care. The implementation of change in health care.","first-page":"91","article-title":"Clinical practice guidelines as a tool for improving patient care","author":"Burgers","year":"2013"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0070","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/00365520600664250","article-title":"Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study","author":"Wolters","year":"2006","journal-title":"Scand J Gastroenterol Suppl."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0075","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.gastro.2006.05.052","article-title":"Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation","volume":"131","author":"Odes","year":"2006","journal-title":"Gastroenterology"},{"issue":"Suppl 3","key":"10.1016\/j.gastrohep.2020.07.001_bib0080","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0085","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0090","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0095","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MCG.0000000000000660","article-title":"World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015","volume":"50","author":"Bernstein","year":"2016","journal-title":"J Clin Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/jgh.14648","article-title":"Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia","volume":"34","author":"Ooi","year":"2019","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0105","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders","author":"Magro","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management","author":"Harbord","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.gastrohep.2012.09.006","article-title":"Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU","volume":"36","author":"Gomoll\u00f3n","year":"2013","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0120","first-page":"257","article-title":"Management\u00a0of Paediatric\u00a0Ulcerative Colitis, Part 1. Ambulatory Care\u2014An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology","volume":"67","author":"Turner","year":"2018","journal-title":"Hepatology and Nutrition. JPGN"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0125","first-page":"292","article-title":"Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis\u2014An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology","volume":"67","author":"Turner","year":"2018","journal-title":"Hepatology and Nutrition. JPGN"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cgh.2009.06.024","article-title":"A systematic prospective comparison of noninvasive disease activity indexes in ulcerative colitis","volume":"7","author":"Turner","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0145","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5- aminosalicylic acid therapy for mildly to moderately active ulcerative colitis, a randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0150","first-page":"971","article-title":"An index of disease activity in patients with ulcerative colitis","volume":"87","author":"Seo","year":"1992","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0155","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0160","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0165","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1472-6963-4-38","article-title":"Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches","volume":"4","year":"2004","journal-title":"BMC Health Serv Res."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0175","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0180","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1572-0241.2006.01007.x","article-title":"Continuous infusion versus bolus adminis- tration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial","volume":"102","author":"Bossa","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0185","first-page":"CD004277","article-title":"Cyclosporine A for induction of remission in severe ulcerative colitis","author":"Shibolet","year":"2005","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0190","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1053\/gast.2001.23983","article-title":"Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis","volume":"120","author":"D\u2019Haens","year":"2001","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0195","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0210-5705(05)71523-5","article-title":"Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review","volume":"28","author":"Garc\u00eda-L\u00f3pez","year":"2005","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0200","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double blind comparison of 4mg\/kg versus 2mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0205","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0016-5085(98)84455-7","article-title":"Effectiveness of cyclosporin A (CsA) in the treatment of active refractory ulcerative colitis (UC)","volume":"114","author":"Svanoni","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0210","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1572-0241.2007.01653.x","article-title":"Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis","volume":"103","author":"Cacheaux","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0215","first-page":"1909","article-title":"Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives","volume":"380","author":"Laharie","year":"2012","journal-title":"Cidosporine versus infliximab in acute severe colitis refractory to intravenous steroids: a randomized study. Lancet"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0225","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience","volume":"94","author":"Cohen","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0230","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","author":"Moskovitz","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Ciclosporin use in acute ulcerative colitis: a long-term experience","volume":"17","author":"Campbell","year":"2005","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0240","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0016-5085(98)84455-7","article-title":"Effectiveness of cyclosporin A (CsA) in the treatment of active refractory ulcerative colitis (UC)","volume":"114","author":"Cheifetz","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0245","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1572-0241.2007.01653.x","article-title":"Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis","volume":"103","author":"Cacheaux","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0250","first-page":"1909","article-title":"Groupe d'Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives","volume":"380","author":"Laharie","year":"2012","journal-title":"Cidosporine versus infliximab in acute severe colitis refractory to intravenous steroids: a randomized study. Lancet"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0255","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","article-title":"Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial","volume":"1","author":"Williams","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0260","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporin in ulcerative colitis: a five-year experience","volume":"94","author":"Cohen","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0265","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","author":"Moskovitz","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0270","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Ciclosporin use in acute ulcerative colitis: a long-term experience","volume":"17","author":"Campbell","year":"2005","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0275","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/MCG.0b013e3181e883dd","article-title":"Cyclosporine is safe and effective in patients with severe ulcerative colitis","volume":"45","author":"Cheifetz","year":"2011","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0280","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/ajg.2017.180","article-title":"Long-Term Efficacy and Safety of\u00a0Cyclosporine\u00a0in a Cohort of Steroid-Refractory Acute SevereUlcerative Colitis\u00a0Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study","volume":"112","author":"Ord\u00e1s","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0285","first-page":"1424","article-title":"Cyclosporine for severe ulcerative colitis","volume":"92","author":"Kornbluth","year":"1997","journal-title":"An user's guide. Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0290","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/gut.2005.081794","article-title":"Remission-induction and steroid-sparing efficacy by oral tacrolimus (FK506) therapy against refractory ulcerative colitis","volume":"55","author":"Ogata","year":"2006","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.21853","article-title":"Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis","volume":"18","author":"Ogata","year":"2012","journal-title":"Inflammatory bowel diseases"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0300","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.21853","article-title":"Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis","volume":"18","author":"Komaki","year":"2012","journal-title":"Inflammatory bowel diseases"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0305","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","article-title":"Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis","volume":"10","author":"Komaki","year":"2016","journal-title":"Journal of Crohn's & colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0310","first-page":"CD005112","article-title":"Tumor necrosis factor alpha blocking agents for induction of remission in ulcerative colitis","volume":"19","author":"Lawson","year":"2006","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0315","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2006.03131.x","article-title":"Systematic review: infliximab therapy in ulcerative colitis","volume":"25","author":"Gisbert","year":"2007","journal-title":"Aliment Pharmacology Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0320","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0325","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomi- zed, placebo-controlled study","volume":"128","author":"Jarnerot","year":"2005","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0330","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/gut.52.7.998","article-title":"Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial","volume":"52","author":"Probert","year":"2003","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0335","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1365-2036.2010.04435.x","article-title":"Clinical trial: colectomy after rescue therapy in ulcerative colitis-3 year follow-up of the Swedish- Danish controlled infliximab study","volume":"32","author":"Gustavsson","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0340","first-page":"231","article-title":"Infliximab in the treatment of steroid-dependent ulcerative colitis","volume":"8","author":"Armuzzi","year":"2004","journal-title":"Eur Rev Med Pharmacil Sci"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0345","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00042737-200411000-00014","article-title":"Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study","volume":"16","author":"Ochsenkuhn","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0350","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0355","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0360","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0365","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0370","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/apt.14410","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0375","first-page":"697","article-title":"Prediction of short and medium-term efficacy of biosimilar infliximab therapy","volume":"11","author":"Gonczi","year":"2017","journal-title":"Do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?. J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0380","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis\u2014results from a multicenter prospective randomized controlled trial and its post hoc analysis","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0385","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/ajg.2016.7","article-title":"Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids","volume":"111","author":"Narula","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0390","first-page":"1","article-title":"for the Groupe d\u2019Etudes Th\u00e9rapeutiques des Affections Inflammatoires Digestives long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab","volume":"0","author":"Laharie","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0395","author":"Ollech","year":"2019","journal-title":"Efficacy and safety of induction therapy with calcineurin inhibitors followed by\u00a0vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0400","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1007\/s10620-007-9760-1","article-title":"A Meta-analysis of antibiotic therapy for active ulcerative colitis","volume":"52","author":"Rahimi","year":"2007","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0405","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/ajg.2010.84","article-title":"Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled mulcenter trial","volume":"105","author":"Ohjusa","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0410","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/apt.12688","article-title":"Adjunct antibiotic combination therapy for steroid-refractory or -dependent ulcerative colitis: an open-label multicentre study","volume":"39","author":"Kato","year":"2014","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0415","doi-asserted-by":"crossref","first-page":"k1407","DOI":"10.1136\/bmj.k1407","article-title":"Secondary peritonitis: principles of diagnosis and intervention","volume":"361","author":"Ross","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0420","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gut.2009.192765","article-title":"Management of acute severe ulcerative colitis","volume":"60","author":"Van Assche","year":"2011","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0425","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1111\/j.1572-0241.2008.02052.x","article-title":"Rising prevalence of venous thromboembolis and its impact on mortality among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0430","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3748\/wjg.15.927","article-title":"Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events","volume":"15","author":"Wang","year":"2009","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0435","first-page":"227","article-title":"Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis","volume":"88","author":"Gonz\u00e1lez-Huix","year":"1993","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0440","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2036.2004.01945.x","article-title":"Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery","volume":"19","author":"Ho","year":"2004","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0445","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1002\/ibd.21634","article-title":"Decision tree for early introduction of res- cue therapy in active ulcerative colitis treated with steroids","volume":"17","author":"Ma\u00f1osa","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0450","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/ibd.20498","article-title":"Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy","volume":"14","author":"Dom\u00e9nech","year":"2008","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0455","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0140-6736(78)91816-0","article-title":"Further experience in the treatment of severe attacks of ulcerative colitis","volume":"2","author":"Truelove","year":"1978","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0460","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.gastrohep.2013.01.002","article-title":"Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)","volume":"36","author":"Cabriada","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0465","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000212075","article-title":"Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis","volume":"80","author":"Ma\u00f1osa","year":"2009","journal-title":"Digestion."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0470","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1053\/j.gastro.2009.08.069","article-title":"Delayed-release oral mesalamine 4.8g\/day (800 mg Tablet) is effective for patients with moderately active ulcerative colitis","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0475","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/ibd.23024","article-title":"Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis","volume":"18","author":"Feagan","year":"2012","journal-title":"Inflammatory bowel diseases"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0480","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/apt.12266","article-title":"Randomised clinical trial: once vs. twice-daily prolonged-release mesalazine for active ulcerative colitis","volume":"37","author":"Flourie","year":"2013","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0485","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","article-title":"Once-daily, high-concentration MMX mesalamine in active ulcerative colitis","volume":"132","author":"Kamm","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0490","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/gut.2008.154302","article-title":"Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial","volume":"58","author":"Kruis","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0495","first-page":"1","article-title":"5-ASA dose-response: maximizing efficacy and adherence","volume":"6","author":"Katz","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0500","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/01.mib.0000231495.92013.5e","article-title":"Medical management of left side ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials","volume":"12","author":"Regueiro","year":"2006","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0505","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2006.02846.x","article-title":"Parkes systematic review: the use of mesalazine in inflammatory bowel disease","volume":"23","author":"Bergman","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0510","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/A:1017987229718","article-title":"Role of 5-Aminosalicylic Acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review","volume":"47","author":"Gisbert","year":"2002","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0515","first-page":"1867","article-title":"A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0520","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2036.2001.00913.x","article-title":"Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study","volume":"15","author":"Vecchi","year":"2001","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0525","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.2004.060103","article-title":"Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy in patients with extensive mild\/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study","volume":"54","author":"Marteau","year":"2005","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0530","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1572-0241.2000.02180.x","article-title":"Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis","volume":"95","author":"Marshall","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0535","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1046\/j.1365-2036.2000.00784.x","article-title":"Efficacy and tolerability of mesalazine foam enema (Salofal foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study","volume":"14","author":"Pokrotnieks","year":"2000","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0540","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00054725-199805000-00001","article-title":"Dose-ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multicentre placebo-controlled trial","volume":"4","author":"Hanauer","year":"1998","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0545","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02236902","article-title":"Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis","volume":"41","author":"Gionchetti","year":"1998","journal-title":"Dis Col Rectum."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0550","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.MIB.0000158386.25660.1e","article-title":"A new oral delivery system for 5-ASA: preliminary clinical findings for MMX","volume":"11","author":"Prantera","year":"2005","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166455","article-title":"Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"11","author":"Manguso","year":"2016","journal-title":"PLoS One."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0560","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF02850196","article-title":"Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study","volume":"18","author":"Rizzello","year":"2001","journal-title":"Adv Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0565","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2036.2002.01298.x","article-title":"Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a double blind placebo-controlled study","volume":"16","author":"Rizzello","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0570","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1046\/j.1365-2036.2003.01609.x","article-title":"Oral beclomethasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study","volume":"17","author":"Campieri","year":"2003","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0575","year":"2003","journal-title":"Clinical Study Report no. RA\/PR\/1405\/001\/00. Chiesi Farmaceutici S.A. Data on file"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0580","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ajg.2015.114","article-title":"Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study","volume":"110","author":"Van Assche","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0585","first-page":"CD007698","article-title":"Oral budesonide for induction of remission in ulcerative colitis","volume":"10","author":"Sherlock","year":"2015","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0590","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily Budesonide MMX\u00ae extended- release tablets induce remission in patients with mild to moderate ulcerative colitis: Results from the CORE 1 study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0595","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active mild-to-moderate ulcerative colitis: results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2020.07.001_bib0600","first-page":"S1","article-title":"udesonide MMX 9 mg for inducing remission in patients with mild-to-moderate ulcerative colitis not adequately controlled with oral 5-asas","volume":"20","author":"Rubin","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0605","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.crohns.2009.09.007","article-title":"Clinical trial: Preliminary efficacy and safety study of a new budesonide-MMX\u00ae 9 mg extended- release tablets in patients with active left-sided ulcerative colitis","volume":"4","author":"D\u2019Haens","year":"2010","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0610","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1053\/gast.1996.v110.pm8964395","article-title":"Oral budesonide versus prednisone in patients with active extensive and left-sided ulcerative colitis","volume":"110","author":"L\u00f6fberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0615","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2010.11.006","article-title":"3g mesalazina granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double blind, double-dummy, randomized trial","volume":"5","author":"Gross","year":"2011","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0620","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/ecco-jcc\/jjx032","article-title":"Budesonide Multimatrix is efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial","author":"Rubin","year":"2017","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0625","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s10620-009-0962-6","article-title":"Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates","volume":"55","author":"Papi","year":"2010","journal-title":"Dig Dis Sci."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0630","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1136\/bmj.2.5104.1077","article-title":"Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: a controlled trial employing restricted sequential analysis","volume":"2","author":"Watkinson","year":"1958","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0635","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gut.3.3.207","article-title":"A double blind controlled trial of prednisolone 21 phosphate suppositories in the treatment of idiopathic proctitis","volume":"3","author":"Lennard Jones","year":"1962","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/00365529209011158","article-title":"An steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis","volume":"27","author":"Danielsson","year":"1992","journal-title":"Scand J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0645","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0016-5085(98)70131-3","article-title":"Budesonide enema for the treatment of active distal ulcerative colitis and proctitis: a dose-ranging study","volume":"115","author":"Hanauer","year":"1998","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0650","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/jgh.13604","article-title":"Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis","volume":"32","author":"Zeng","year":"2017","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0655","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gut.40.6.775","article-title":"Rectal corticosteroids versus alternative treatments in ulcerative colitis: a metaanalisis","volume":"40","author":"Marshall","year":"1997","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0660","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1365-2036.1998.00299.x","article-title":"Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis","volume":"12","author":"Campieri","year":"1998","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0665","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10350-004-6687-x","article-title":"Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis","volume":"46","author":"Bar-Meir","year":"2003","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0670","first-page":"1345","article-title":"Controlled, open, randomized multicentre trial com- paring the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis","volume":"51","author":"Hammond","year":"2004","journal-title":"Hepatogastroen- terology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0675","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2036.2007.03349.x","article-title":"The efficacy of rectal beclomethasone dipropionate vs 5-aminosalicylic acid in mild to moderate distal ulcerative colitis","volume":"26","author":"Manguso","year":"2007","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0680","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00042737-199606000-00010","article-title":"Beclometahsone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3 mg\/2 g) as retention enemas in active ulcerative proctitis","volume":"8","author":"Mulder","year":"1996","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0685","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerativa colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0690","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0210-5705(02)70275-6","article-title":"Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal","volume":"25","author":"Gisbert","year":"2002","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0695","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1053\/gast.1996.v110.pm8613046","article-title":"Methotrexate in chronic active UC: a double-blind, randomised, Israeli multicenter trial","volume":"110","author":"Oren","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0700","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.gastro.2015.10.050","article-title":"Methotrexate is not Superior to Placebo in Inducing Steroid-free Remission, but Induces Steroid-free Clinical Remission in a Larger Proportion of Patients with Ulcerative Colitis","volume":"150","author":"Carbonnel","year":"2016","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0705","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/ibd.21246","article-title":"Efficacy of methotrexate in ulcerative colitis: failure or promise","volume":"16","author":"Herfarth","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0710","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1053\/j.gastro.2018.06.046","article-title":"Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis","volume":"155","author":"Herfarth","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0715","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulceratvie colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0720","author":"Sands","year":"2019","journal-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0725","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(89)92232-0","article-title":"Treatment of refractory ulcerative colitis with cyclosporin enemas","volume":"1","author":"Brynskov","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0730","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(89)90330-9","article-title":"Treatment of chronic proctosigmoiditis with cyclosporin enemas","volume":"2","author":"Ranzi","year":"1989","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0735","first-page":"640","article-title":"Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis","volume":"88","author":"Sandborn","year":"1993","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0740","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0016-5085(94)90394-8","article-title":"A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis","volume":"106","author":"Sandborn","year":"1994","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0745","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2017.02.027","article-title":"Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis","volume":"15","author":"Lawrance","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0750","doi-asserted-by":"crossref","unstructured":"Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214-20. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009;15:193-8.","DOI":"10.1111\/j.1365-2036.2008.03841.x"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0755","first-page":"231","article-title":"Infliximab in the treatment of steroid-dependent ulcerative colitis","volume":"8","author":"Armuzzi","year":"2004","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0760","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","article-title":"Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission","volume":"19","author":"Armuzzi","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0765","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/MIB.0000000000000115","article-title":"Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis","volume":"20","author":"Armuzzi","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0770","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0775","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0780","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0785","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5009\/gnl15042","article-title":"Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials","volume":"10","author":"Zhang","year":"2016","journal-title":"Gut Liver"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0790","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3748\/wjg.v13.i16.2328","article-title":"Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study","volume":"13","author":"Peyrin-Biroulet","year":"2007","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0795","first-page":"788","article-title":"Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-na\u00efve and non-na\u00efve patients","volume":"52","author":"Iborra","year":"2017","journal-title":"Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0800","first-page":"e11897","volume":"97","author":"Tursi","year":"2018","journal-title":"Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers Medicine (Baltimore)."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0805","first-page":"85","volume":"146","author":"Sandborn","year":"2014","journal-title":"Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology"},{"issue":"1.","key":"10.1016\/j.gastrohep.2020.07.001_bib0810","article-title":"Golimumab induction and maintenance for moderate-to-severe ulcerative colitis: results from the GO-COLITIS (Golimumab: a Phase 4 UK, open label, single arm study on its utilization and impact in ulcerative colitis)","volume":"5","author":"Probert","year":"2018","journal-title":"BMJ open Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0815","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ibd\/izy219","article-title":"Early mucosal healing predicts favorable outcomes in patients with moderate to severe ulcerative colitis treated with golimumab: data from the real-life BE-SMART cohort","volume":"25","author":"Bossuyt","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0820","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.dld.2018.11.002","article-title":"Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence","volume":"51","author":"Olivera","year":"2019","journal-title":"Dig Liver dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0825","doi-asserted-by":"crossref","first-page":"6352","DOI":"10.3748\/wjg.v21.i20.6352","article-title":"Metaanalisis of the effectivenes and safety of Vedolizumab for Ulcerative colitis","volume":"21","author":"Yu Jin","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0830","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0835","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0840","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0845","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0850","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.gastro.2008.04.023","article-title":"A randomized, double-blind, sham-controlled study of granulocyte\/monocyte apheresis for active ulcerative colitis","volume":"135","author":"Sands","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0855","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000431149","article-title":"Granulocyte\/Monocyte Adsorptive Apheresis in Moderate to Severe Ulcerative Colitis \u2013 Effective or Not?","volume":"92","author":"Kruis","year":"2015","journal-title":"Digestion."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0860","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.dld.2007.01.001","article-title":"Treatment of patients with acute ulcerative colitis: convencional corticos- teroid therapy (MP) versus granulocytapheresis (GMA): a pilot study","volume":"39","author":"Bresci","year":"2007","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0865","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000080079","article-title":"Adsorptive granulocyte and monocyte apheresis ver- sus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis","volume":"70","author":"Hanai","year":"2004","journal-title":"Digestion."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0870","first-page":"534","article-title":"Randomized, double-blind, placebo-controlled trial of CCR9-targeted leukapheresis treatment of ulcerative colitis patients","volume":"11","author":"Eberhardson","year":"2017","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0875","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ecco-jcc\/jjy023","article-title":"Addition of granulocyte\/monocyte apheresis to oral prednisone for steroid-dependent ulcerative colitis: A randomized, multicentre, clinical trial","volume":"12","author":"Dom\u00e9nech","year":"2018","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0880","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00535-011-0499-2","article-title":"Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry","volume":"47","author":"Cabriada","year":"2012","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0885","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/ecco-jcc\/jjw032","article-title":"Safety and Ef cacy of Granulocyte\/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insuf cient Response or Intolerance to Immunosuppressants and\/or Biologics [the ART Trial]: 12-week Interim Results","author":"Dignass","year":"2016","journal-title":"Journal of Crohn's and Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0890","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1016\/j.crohns.2013.06.012","article-title":"Granulocytapheresis in steroiddependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study","volume":"7","author":"Sacco","year":"2013","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0895","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-230X-13-27","article-title":"Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA","volume":"13","author":"Yokoyama","year":"2013","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0900","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.crohns.2014.01.027","article-title":"A large scale prospective, observacional study oof leuckcytapheresis for ulcerative colitis: tratment outcomes of 847 patients in clinical practice","volume":"8","author":"Yokoyama","year":"2014","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0905","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/ajg.2009.453","article-title":"An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment","volume":"104","author":"Sakuraba","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0910","first-page":"e0157259","volume":"11","author":"Shi","year":"2016","journal-title":"Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis PloS1"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0915","first-page":"1","author":"Costello","year":"2017","journal-title":"Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0920","doi-asserted-by":"crossref","first-page":"8941340","DOI":"10.1155\/2018\/8941340","article-title":"Protocol for Fecal Microbiota Transplantation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"2018","author":"Fang","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0925","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/MIB.0000000000001132","article-title":"Single Delivery of High-diversity Fecal Microbiota Preparation by Colonoscopy is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis","volume":"23","author":"Jacob","year":"2017","journal-title":"Inflamm Bowel disease"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0930","first-page":"903","volume":"23","author":"Uygun","year":"2017","journal-title":"Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0935","first-page":"1","article-title":"Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease","author":"Derwa","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0940","first-page":"1202","article-title":"The probiotic preparation","volume":"7","author":"Sood","year":"2009","journal-title":"VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0945","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0950","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1572-0241.2000.01940.x","article-title":"Meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis","volume":"95","author":"Cohen","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0955","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1572-0241.2000.02185.x","article-title":"Long-term use of mesalamine (Rowasa) suppo- sitories in remission maintenance of ulcerative proctitis","volume":"95","author":"Hanauer","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0960","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0016-5085(88)90569-0","article-title":"5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis","volume":"94","author":"Biddle","year":"1988","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0965","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1572-0241.1998.228_a.x","article-title":"Maintenance treatment of ulcerative proctitis with mesalazine suppositories: A double-blind placebo-controlled trial","volume":"93","author":"D\u2019Albasio","year":"1998","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0970","first-page":"1143","article-title":"Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study","volume":"92","author":"d'Albasio","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0975","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ibd.20158","article-title":"Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study","volume":"13","author":"Yokoyama","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0980","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","article-title":"Meta- analysis: the efficacy of azathioprine and mercaptopurine in ulcerativa colitis","volume":"30","author":"Gisbert","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0985","first-page":"CD000478","article-title":"Azathioprine and 6mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0990","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib0995","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1038\/ajg.2009.410","article-title":"Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal","volume":"104","author":"Cassinotti","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1000","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1097\/MIB.0000000000000400","article-title":"Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines Withdrawal","volume":"21","author":"Moreno-Rincon","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1005","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/gut.50.4.485","article-title":"The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review","volume":"50","author":"Fraser","year":"2002","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1010","first-page":"CD007560","author":"Wang","year":"2015","journal-title":"Metotrexate in maintenance of UC."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/MIB.0b013e31828133e8","article-title":"Methotrexate in Ulcerative Colitis: A Nationwide Retrospective Cohort from the Veterans Affairs Health Care System","volume":"19","author":"Khan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1020","first-page":"397","volume":"5","author":"Ma\u00f1osa","year":"2011","journal-title":"Methotrexate in ulcerative colitis: A Spanish multicentric study on clinical use and efficacy JCC"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.dld.2011.09.015","article-title":"The use of methotrexate for treatment of inflammatory bowel disease in clinical practice","volume":"44","author":"Saibeni","year":"2012","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1744-9987.2012.01064.x","article-title":"Intermittent Granulocyte and Monocyte Apheresis Versus Mercaptopurine for Maintaining Remission of Ulcerative Colitis: A Pilot Study","volume":"16","author":"Sakuraba","year":"2012","journal-title":"Ther Apher Dial."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1035","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.gastro.2009.06.061","article-title":"Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab","volume":"137","author":"Sandborn","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1040","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1045","first-page":"96","volume":"146","author":"Sandborn","year":"2014","journal-title":"Subcutaneous Golimumab manteins Clinical Response in in Patients With Moderate-to-Severe Ulcerative Colitis Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1050","first-page":"e168","volume":"7","author":"Gibson","year":"2016","journal-title":"Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year) Clin Transl Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1055","first-page":"1053","volume":"12","author":"Reinisch","year":"2018","journal-title":"Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1060","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/MEG.0000000000001177","article-title":"Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis","volume":"30","author":"O\u2019Connell","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1065","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/MIB.0000000000001144","article-title":"Clinical outcomes of golimumab as first, second or third Anti-TNF agent in patients with moderate-to-severe ulcerative colitis","volume":"23","author":"Taxonera","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1070","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1080","first-page":"400","volume":"11","author":"Loftus","year":"2017","journal-title":"Long term efficacy of Vedolizumab for UC) Long term efficacy of Vedolizumab for UC JCC"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1085","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s003840100346","article-title":"Longer term outcome of steroid refractory ulcerative colitis treated with intravenous cyclosporine without subsequent oral cyclosporine maintenance therapy","volume":"17","author":"Rolny","year":"2002","journal-title":"Int J Colorectal Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1095","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1046\/j.1365-2036.2002.01385.x","article-title":"Azathioprine without oral ciclosporine in the long-term maintenance of remission induced by intravenous ciclosporine in severe, steroid-refractory ulcerative colitis","volume":"16","author":"Dom\u00e9nech","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Cyclosporine use in acute ulcerative colitis: a long-term experience","volume":"17","author":"Campbell","year":"2005","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1105","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.1999.01149.x","article-title":"Intravenous cyclosporine in ulcerative colitis: a five-year experience","volume":"94","author":"Cohen","year":"1999","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1110","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.cgh.2006.04.001","article-title":"Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis","volume":"4","author":"Moskovitz","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1115","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1590-8658(03)00270-6","article-title":"Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome","volume":"35","author":"Campbell","year":"2003","journal-title":"Dig Liver Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-230X-7-13","article-title":"Colectomy rate in steroid-refractory colitis initially responsive to cyclosporine: a long-term retrospective cohort study","volume":"7","author":"Actis","year":"2007","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/ibd.20843","article-title":"Long-term outcome after admission for acute ulcerative colitis in Oxford","volume":"15","author":"Bojic","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cgh.2018.08.081","article-title":"Groupe d'Etude Th\u00e9rapeutique des Affections Inflammatoires du tube Digestif. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis","volume":"17","author":"Pellet","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.12651","article-title":"Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis","volume":"39","author":"Casta\u00f1o-Milla","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"10218","key":"10.1016\/j.gastrohep.2020.07.001_bib1140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","article-title":"Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study","volume":"395","author":"Ol\u00e9n","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1145","series-title":"La vida emergente","author":"Luisi","year":"2010"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1150","series-title":"Stumbling on Happiness","author":"Gilbert","year":"2005"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2036.2011.04701.x","article-title":"Review article: defining remission in ulcerative colitis","volume":"34","author":"Travis","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1170","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1175","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.cgh.2018.10.036","article-title":"Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis","volume":"17","author":"Vande Casteele","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1180","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1190","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1195","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more costeffective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1200","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1205","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1210","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1215","article-title":"Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease","author":"Fernandes","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2020.07.001_bib1220","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052030265X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057052030265X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:45:12Z","timestamp":1759322712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057052030265X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":244,"alternative-id":["S021057052030265X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.07.001","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gu\u00eda GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodolog\u00eda GRADE","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}